Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review.

ABSTRACT: Memantine is licensed for moderate-to-severe Alzheimer's disease (AD). National Institute for Clinical Excellence (NICE) guidance does not recommend the use of memantine in combination with cholinesterase inhibitors (acetylcholinesterase inhibitor (AChEI)). The underpinning meta-analysis was disputed by the manufacturer. To compare the efficacy of AChEI monotherapy with combination memantine and AChEI therapy in patients with moderate-to-severe AD and to examine the impact of including unpublished data on the results. Systematic review and meta-analysis of randomised controlled trials. The Cochrane Dementia Group trial register, ALOIS, searched for the last time on 3 May 2011. Data from four domains (clinical global, cognition, function, behaviour and mood) were pooled. Sensitivity analyse

SUBMITTER: Farrimond LE 

PROVIDER: S-EPMC3378937 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature